Holen Sie sich die Stockscreener-App
62.44
7.12%
-4.79
Vorhandelsmarkt:
60.51
-1.93
-3.09%
Schlusskurs vom Vortag:
$67.23
Offen:
$63.71
24-Stunden-Volumen:
645.75K
Relative Volume:
1.03
Marktkapitalisierung:
$3.43B
Einnahmen:
$155.82M
Nettoeinkommen (Verlust:
$-40.42M
KGV:
-87.94
EPS:
-0.71
Netto-Cashflow:
$3.58M
1W Leistung:
-8.86%
1M Leistung:
-0.30%
6M Leistung:
-18.06%
1J Leistung:
-1.20%
1-Tages-Spanne:
$61.09
$64.73
1-Wochen-Bereich:
$59.45
$69.09
52-Wochen-Spanne:
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Firmenname
Arcellx Inc
Sektor
Branche
Telefon
240-327-0603
Adresse
800 BRIDGE PARKWAY, REDWOOD CITY
Vergleichen Sie ACLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
62.44 | 3.43B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-07 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-10-30 | Eingeleitet | TD Cowen | Outperform |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-05-18 | Eingeleitet | Truist | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-14 | Eingeleitet | Stifel | Buy |
| 2023-02-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-13 | Fortgesetzt | BofA Securities | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-27 | Eingeleitet | Needham | Buy |
| 2022-07-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-03-01 | Eingeleitet | BofA Securities | Buy |
| 2022-03-01 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Arcellx Inc Aktie (ACLX) Neueste Nachrichten
Arcellx, Inc. (NASDAQ:ACLX) Stake Lessened by Corebridge Financial Inc. - Defense World
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Benzinga
What You Didn’t Know About Arcellx Inc (NASDAQ: ACLX) This Week - stocksregister.com
Arcellx Inc (ACLX) rating initates by Redburn Atlantic - knoxdaily.com
Teacher Retirement System of Texas Purchases 1,505 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
In 2025, Will Arcellx Inc (NASDAQ: ACLX) Be Bullish Or Bearish? - Stocks Register
How To Trade (ACLX) - news.stocktradersdaily.com
Swiss National Bank Buys 500 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Raymond James Financial Inc. Acquires New Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors - BioSpace
Arcellx Inc Announces Board Changes for Strategic Growth - TipRanks
Arcellx names new board members, gears up for 2026 launch By Investing.com - Investing.com Australia
Arcellx Appoints Andrew Galligan And Kristin Myers To Its Board Of Directors -March 20, 2025 at 04:42 pm EDT - MarketScreener
Arcellx names new board members, gears up for 2026 launch - Investing.com
Arcellx Bolsters Commercial Strategy: Key Healthcare Veterans Join Board for Myeloma Drug Launch - Stock Titan
Arcellx director Kavita Patel sells $107,460 in common stock By Investing.com - Investing.com Australia
Arcellx director Kavita Patel sells $107,460 in common stock - Investing.com India
Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month - The Manila Times
Charles Schwab Investment Management Inc. Buys 14,992 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Impressive Safety Data Leaves Doubts (NASDAQ:ACLX) - Seeking Alpha
Bank of New York Mellon Corp Buys 27,350 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
US Bancorp DE Has $462,000 Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
ACLX June 20th Options Begin Trading - Nasdaq
Arcellx (NASDAQ:ACLX) Shares Gap Up – Time to Buy? - Defense World
Principal Financial Group Inc. Trims Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Myesha Lacy - ir-impact.com
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
Need To Know: Analysts Just Made A Substantial Cut To Their Arcellx, Inc. (NASDAQ:ACLX) Estimates - Simply Wall St
We're Not Worried About Arcellx's (NASDAQ:ACLX) Cash Burn - Yahoo Finance
New York State Common Retirement Fund Has $1.55 Million Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
HC Wainwright Predicts Arcellx’s Q1 Earnings (NASDAQ:ACLX) - Defense World
Optimistic Buy Rating for Arcellx Inc: Promising CAR-T Therapy and Strong Financial Position Highlighted - TipRanks
Arcellx Reports Promising 2024 Financial and Clinical Progress - MSN
Arcellx (NASDAQ:ACLX) Posts Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
State of New Jersey Common Pension Fund D Purchases New Stake in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Why Arcellx Inc Stocks Are on the Rise - TipRanks
Arcellx Inc’s Anito-cel: Anticipated Market Leader with Strong Efficacy, Safety, and Financial Position - TipRanks
Arcellx Inc: Buy Rating Affirmed on Promising Anito-cel Therapy and Strong Financial Position - TipRanks
Arcellx Inc’s Anito-cel Therapy: Promising Clinical Results and Strategic Partnerships Support Buy Rating - TipRanks
Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating - TipRanks
Arcellx, Inc. (NASDAQ:ACLX) Shares Bought by Rhumbline Advisers - Defense World
Rami Elghandour Sells 38,300 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights - BioSpace
Arcellx earnings missed by $0.31, revenue fell short of estimates - Investing.com UK
Arcellx reports FY24 EPS ($2.00), consensus ($1.50) - TipRanks
Arcellx CEO Rami Elghandour sells $2.38 million in stock By Investing.com - Investing.com South Africa
Arcellx CEO Rami Elghandour sells $2.38 million in stock - Investing.com
Finanzdaten der Arcellx Inc-Aktie (ACLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):